PathAI announced its partnership with GSK on HORIZON, a randomized Phase 2b non-alcoholic steatohepatitis clinical trial. The trial will measure improvements in liver histology with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis. PathAI’s role will be to generate, digitize, and analyze liver biopsy slides for central pathologist evaluation in addition to AI-powered histologic evaluation using PathAI’s AI-based Measurement of NASH Histology tool. AIM-NASH metrics will be included as exploratory endpoints in this study. PathAI will provide kitting, logistics, lab and analytical services to generate and analyze digitized H&E and Masson’s Trichome data for both pathologist consensus scoring, facilitated by PathAI’s Contributor Pathologist Network, and quantitative histologic evaluation, enabled by AIM-NASH. This trial will utilize PathAI’s full end-to-end anatomical pathology services through the PathAI Biopharma Lab, located in Memphis, TN. PathAI’s biopharma lab will receive and accession trial subject biopsies, stain tissue sections, and create slides. The stained slides for each case will then be scanned using a whole slide image scanner and will be uploaded to PathAI’s digital pathology viewer, AISight for assessment by pathologists and via AIM-NASH.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal Treatment
- Scynexis, GSK announce exclusive agreement to commercialize, develop Brexafemme
- AnaptysBio ‘encouraged’ by GSK phase 3 trial results
- GSK says Phase III Ruby trial demonstrates Jemperli plus chemotherapy potential
- GSK Pharma put volume heavy and directionally bearish